Actively Recruiting
A Study Utilizing Escitalopram in Glioma Patients
Led by University of Nebraska · Updated on 2026-04-17
20
Participants Needed
1
Research Sites
534 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glioma is a cancer of glial cells, a class of tissue supporting neuronal function in the brain. As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also from therapy such as cranial radiation and chemotherapy, which degrades neuronal function. There is evidence that serotonin selective reuptake inhibitors (SSRIs), such as escitalopram, improve cognition or prevent cognitive decline and may also improve outcomes critical to overall survival including functional independence, psychosocial stability, and quality of life. This pilot study will evaluate the effectiveness of the selective serotonin reuptake inhibitor (SSRI) escitalopram for treating cognitive impairment in newly diagnosed grade IV glioma over a 17 week treatment period.
CONDITIONS
Official Title
A Study Utilizing Escitalopram in Glioma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Grade IV glioma confirmed by pathology
- Newly diagnosed and planned to receive chemotherapy and/or radiation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 or equivalent
- At least 19 years old
- Life expectancy longer than 6 months
- Able to provide written informed consent
- Negative urine pregnancy test for women who can become pregnant
- Female participants must be post-menopausal, surgically sterilized, or willing to use two forms of contraception
You will not qualify if you...
- Visual field defects that interfere with participation in tests
- Unable to undergo MRI
- Severe kidney impairment with Glomerular Filtration Rate (GFR) less than 30 mL/minute
- Screening positive for depression or anxiety
- Currently taking antidepressants such as SSRIs or NSRIs
- History of intolerance to SSRIs or NSRIs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
Research Team
M
Michaela K Savine, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here